All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit Know AML.
The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, and AbbVie. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Identifying fusions/translocations with NGS: An analysis of myeloMATCH
Do you know... What was the primary reason NGS was incorporated into the myeloMATCH screening workflow?
During the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, data were presented from a concordance analysis of the myeloMATCH initial screening program, evaluating the use of next‑generation sequencing (NGS) to identify clinically relevant fusions in patients with acute myeloid leukemia or myelodysplastic syndrome.
The original workflow used NGS solely to determine DNA alterations. Karyotype and fluorescence in situ hybridization (FISH) assays were used to identify RNA alterations and fusions and to assign patients to the most relevant subprotocol treatment trial within the myeloMATCH portfolio, based on World Health Organization subclassification and European LeukemiaNet risk stratification. However, comparison of the NMAv2 NGS assay with karyotype and FISH assays revealed high concordance, informing updates to the myeloMATCH initial screening study workflow.
This educational resource is independently supported by ThermoFisher. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which AML-related topic do you currently need the most practical guidance on?
